Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board has created the technology that led to the development of what is known as Listeria cancer vaccines.

Based in North Brunswick, New Jersey, Advaxis is experimenting on its therapeutic cancer vaccines, which it expects will enhance the immune system's cancer-fighting abilities. The firm's proprietary Listeria monocytogenes based system utilizes two immunological mechanisms (Innate and Classical Immunity) in order to develop safer and more effective Listeria based cancer vaccines.

Advaxis is the exclusive licensee of the patented Listeria platform technology that can elicit anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis has entered a Phase 1-2 clinical trial.

The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.

NEWS: